Verion incorporated nuclear regulatory commission materials license

Each license requires use of the radioactive material in specified locations, using limited radioactive materials in accordance with approved operating procedures.

If you wish to apply for a radioactive material license, the Radiological Health Section has many licensing guides that can assist you in preparation of an application. Please feel free to contact staff at for assistance. Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol "PNT".

Research Alliance Corp. RACA is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry. RA Capital is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, strategic partnerships in radioisotope supply, manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization. A full description of the terms of the business combination is provided in a registration statement on Form S-4 filed with the SEC by Therapeutics Acquisition Corp.

RACA and POINT and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed business combination described in this press release under the rules of the SEC.

These documents can be obtained free of charge from the sources indicated above. This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available.

In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove to be accurate.

Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

View source version on businesswire. The Oracle of Omaha knows how to beat inflation. History: Sec. No report is required if the device is transferred to the specific licensee in order to obtain a replacement device; viii shall transfer the device to another general licensee: A where the device remains in use at a particular location.

In addition, persons who receive, acquire, possess, use, or transfer 1 or more calibration or reference sources pursuant to these general licenses: i shall not possess at any 1 time, at any 1 location of storage or use, more than 5 microcuries of americium, 5 microcuries of plutonium, or 5 microcuries of radium in such sources; ii shall not receive, possess, use, or transfer such source unless the source, or the storage container, bears a label which includes 1 of the following statements, as appropriate, or a substantially similar statement which contains the information called for in 1 of the following statements, as appropriate: A The receipt, possession, use and transfer of this source, Model , Serial No.

Name of manufacturer of importer B The receipt, possession, use and transfer of this source, Model , Serial No. Name of manufacturer or importer iii shall not transfer, abandon, or dispose of such source except by transfer to a person authorized by a license from the department, the US nuclear regulatory commission, an agreement state or a licensing state to receive the source; iv shall store such source, except when the source is being used, in a closed container adequately designed and constructed to contain americium, plutonium, or radium which might otherwise escape during storage; and v shall not use such source for any purpose other than the calibration of radiation detectors or the standardization of other sources.

The generally licensed physician shall furnish on department form MRH the following information and such other information as may be required by that form: i name and address of the generally licensed physician; ii a statement that the generally licensed physician is a duly licensed physician authorized to dispense drugs in the practice of medicine in Montana; and iii a statement that the generally licensed physician has appropriate radiation measuring instruments to carry out the diagnostic procedures for which he proposes to use radioactive material under the general license of this 8 and that he is competent in the use of such instruments.

The physician, clinical laboratory or hospital shall furnish on department form MRH the following information and such other information as may be required by that form: i name and address of the physician, clinical laboratory or hospital; ii the location of use; and iii a statement that the physician, clinical laboratory or hospital has appropriate radiation measuring instruments to carry out in vitro clinical or laboratory tests with radioactive material as authorized under the general license in a above and that such tests will be performed only by personnel competent in the use of such instruments and in the handling of the radioactive material.

Its receipt, acquisition, possession, use, and transfer are subject to the regulations and a general license of the US nuclear regulatory commission or of a state with which the commission has entered into an agreement for the exercise of regulatory authority.

Name of manufacturer B This radioactive material shall be received, acquired, possessed, and used only by physicians, clinical laboratories or hospitals and only for in vitro clinical or laboratory tests not involving internal or external administration of the material, or the radiation therefrom, to human beings or animals.

Its receipt, acquisition, possession, use and transfer are subject to the regulations and a general license of a licensing state. Name of manufacturer e The physician, clinical laboratory or hospital possessing or using radioactive material under the general license of a above shall report in writing to the department, any changes in the information furnished by him in the "Certificate--In Vitro Testing with Radioactive Material Under General License", department form MRH Rule: Prev Up Next.

Add to Favorites.